Research never stops

Michael Shalmi

Mr Michael Shalmi (born in 1965) was appointed Member of the Supervisory Board on 14 June 2017 for a term of two years. His current term will expire at the end of the AGM held in the year 2019. Since January 2017, Mr Michael Shalmi has been Managing Director, Head of Principal Investments of Novo Holdings A/S. From 2009 to 2016, he served as Senior Partner at Novo Holdings A/S where he led at first the division Novo Growth Equity and then for two years the division Large Investments. In this role, he was responsible for the strategic long-term investments in life science. Prior to his career at Novo Holdings A/S, he spent 15 years at Novo Nordisk A/S where he held a number of different international management positions in research, clinical development as well as marketing and management, lastly as Vice President, Global Development, Clinical Operations Management. Prior to working at Novo Nordisk, he was research associate at the universities in Copenhagen and Manchester.

During his career, Michael Shalmi gained extensive expertise in medicine and especially focused on drug and product development and on the development of commercialisation strategies. Mr Shalmi holds further positions as a member of other statutory supervisory boards such as Orexo AB, Synlab Ltd., Momentum Gruppen A/S, ERT Inc., ERT HoldCo A/S, Xellia HoldCo A/S and Novo Invest 1 A/S.

Mr Shalmi is a Danish citizen and received his Doctorate of Medicine from the University in Copenhagen and his MBA degree from the Scandinavian International Management Institute.